Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Denecimig - Novo Nordisk

Next Previous
Drug Profile

Denecimig - Novo Nordisk

Alternative Names: Coagulation factor VIII mimetic antibody - Novo Nordisk; FREHEMGO; Frehemgo; FVIII mimetic antibody - Novo Nordisk; Mim-8; NN-7769; NN0365-3769; NNC-0365-3769; NNC0365-0005-3769; NNC0365-3769 A

Latest Information Update: 28 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Developer Genmab; Novo Nordisk
  • Class Antihaemorrhagics; Bispecific antibodies
  • Mechanism of Action Factor VIII replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Haemophilia A
  • Preclinical Haemophilia B

Most Recent Events

  • 21 Sep 2026 Novo Nordisk plans a phase III trial for Haemophilia A in Argentina, Australia, Brazil, Canada, Denmark, France, Germany, Greece, India, Italy, Japan, Malaysia, Poland, South Africa, Spain, Turkey, United Kingdom, and USA (SC) in October 2026 (NCT07830732).
  • 17 Sep 2026 Preregistration for Haemophilia A (In adolescents, In adults, Treatment-experienced, In the elderly) in European Union (SC)
  • 17 Sep 2026 Preregistration for Haemophilia A (In infants, In children, In adolescents, In adults, In the elderly) in European Union (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top